Last reviewed · How we verify
NCT04197726: REST
Glycaemic Response to High REsistant STarch Bread
NA trial testing sbeIIa/b white bread in Blood Glucose Response in 21 participants. Completed in 30 April 2021.
30 April 2021
Quick facts
| Lead sponsor | Quadram Institute Bioscience |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | triple |
| Primary purpose | basic science |
| Enrollment | 21 |
| Start date | 6 January 2020 |
| Primary completion | 30 April 2021 |
| Estimated completion | 30 April 2021 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- sbeIIa/b white bread
- Control white bread
Conditions studied
- Blood Glucose Response — all drugs for Blood Glucose Response →
Sponsor
Quadram Institute Bioscience
Who can join
Adults 18 to 65, any sex, with Blood Glucose Response. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluates if the consumption of one sbeIIa/b white bread with high resistant starch content will result in a lower blood glucose response and increased satiety compared with reference white bread. All participants will be asked to consume once the sbeIIa/b white bread and the reference white bread during different visits.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effect of high-amylose <i>starch branching enzyme II</i> wheat mutants on starch digestibility in bread, product quality, postprandial satiety and glycaemic response.
Corrado M, Ahn-Jarvis JH, Fahy B, Savva GM, et al · · 2022 · cited 11× · PMID 35079762 · DOI 10.1039/d1fo03085j
Verify or expand the search:
- PubMed search for NCT04197726
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Quadram Institute Bioscience trials
Trials by the same sponsor.
- NCT07142759 — Investigating the Impact of Vitamin D Biofortified Tomatoes on Serum Levels of 25(OH)D · NA · enrolling by invitation
- NCT06518343 — Trimethylamine N-oxide Effects of a Pomegranate Supplement Simultaneously With Carnitine (TESSA) · NA · active not recruiting
- NCT06145867 — A Feasibility Study: Assessing Photobiomodulation in Myalgic Encephalomyelitis · NA · enrolling by invitation
- NCT05740462 — Hydroponic Fortification and Dietary App Effect on Nutrients Level (Harvest) · NA · enrolling by invitation
- NCT05317429 — Glycaemic Responses to Carbohydrate-rich Meals (GlyCarb) · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04197726 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Quadram Institute Bioscience
- Last refreshed: 17 February 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04197726.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing